ACSS2 and glioblastoma: Indeed, in astrocytes by concurrent insertion of a BRAFV600E mutation and deletion of TP53 and PTEN, which are common oncogenic alterations in GBM, the expression of ACSS2 increased seven-fold and accordingly the cytosolic pool of acetyl-CoA [34].